Frontlight ResearchEarly access
CompletedNo phase
L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
Key facts
- Who runs it
- Beijing Friendship Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 24 people enrolled
- Started
- 1 Aug 2023
- Ended
- 1 Aug 2026
- Type of study
- Interventional
- Treatments tested
- L-DEP and PD-1 antibody
- Record updated
- 16 September 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Diagnosed as lymphoma-Hemophagocytic Lymphohistiocytosis
- EBV-DNA in peripheral blood > 1000 copies/ml or EBER detected in tissue specimens
- Age 18~70，gender is not limited
- Estimated survival time ≥ 1 month
- Cardiac ultrasound LVEF≥50%; No Active bleeding of the internal organs(digestive tract, lung, brain, etc.); If the patient has dyspnea, oxygenation index >250
- Signed informed consent
Who cannot take part
- Accumulated dose of doxorubicin above 400mg/m2 、epirubicin above 750mg/m2、pirarubicin above 800mg/m2 or the patients treated with anthracycline induced cardiovascular disease
- Heart function above grade II (NYHA)
- Allergic to pegylated liposomal doxorubicin，etoposide，or PD-1 antibody
- HIV antibody positivity
- Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable)
- Severe myocardial injury：TNT、TNI、CK-MB > 3 ULN
- Pregnancy or lactating Women
- Thyroid dysfunction
- Participate in other clinical research at the same time
- The researchers considered that patients are not suitable for the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The efficacy and safety of L-DEP (aspargase, liposomal doxorubicin, etoposide, and methylprednisolone) regimen combined with PD-1 Antibody an induction therapy for Epstein-Barr virus (EBV)-positive lymphoma-associated hemophagocytic lymphohistiocytosis.
The group in the trial
- L-DEP and PD-1 antibodyTreatment being tested
aspargase, liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Efficacy and Safety of L-DEP Regimen Combined With PD-1 Antibody an Induction Therapy for Epstein-Barr Virus (EBV)-Positive Lymphoma-associated Hemophagocytic Lymphohistiocytosis
- Record updated
- 16 September 2026